Pfizer buys ReViral to add RSV drug candidate to vaccine program

7 April 2022

The Novo Holdings portfolio company ReViral has been acquired by US pharma giant Pfizer (NYSE: PFE) for up to $525 million in total deal value.

Founded in 2011, ReViral has bases in London, UK, and Research Triangle Park, North Carolina, and is a privately-held clinical-stage biopharma focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).

Pfizer says that this acquisition complements the vaccine candidate in development for RSV, which is a respiratory pathogen that can lead to severe and life-threatening lower respiratory tract infections (LRTIs) in high-risk populations, including young infants, immunocompromised individuals, and older adults. It is estimated to infect approximately 64 million people, resulting in about 160,000 deaths, globally each year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK